Stage IV Hepatocellular Carcinoma AJCC v8 Clinical Trials
29 clinical trials for Stage IV Hepatocellular Carcinoma AJCC v8 across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers — RECRUITING · NA
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer — RECRUITING · PHASE2
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial — RECRUITING · PHASE1
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer — RECRUITING · PHASE1
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial — RECRUITING · PHASE3
- Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer — RECRUITING · PHASE1
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
- Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
- Intravital Microscopy in Human Solid Tumors — RECRUITING · NA
- AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease — RECRUITING · PHASE1
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer — RECRUITING · PHASE1
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer — RECRUITING · PHASE2
- Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma — RECRUITING · PHASE2
- A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab — TERMINATED · PHASE2
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver — ACTIVE_NOT_RECRUITING · PHASE2
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer — TERMINATED · PHASE1
- Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma — SUSPENDED · PHASE1
- Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events — ACTIVE_NOT_RECRUITING · NA
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
- Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) — ACTIVE_NOT_RECRUITING · NA
- Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant — TERMINATED · PHASE2
- IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE2
- 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer — COMPLETED · PHASE2
- An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer — COMPLETED · NA
- Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer — COMPLETED · PHASE2
- Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma — COMPLETED · NA
Refine this search